Chronic Liver Diseases Therapeutics Market, by Treatment Type (Antiviral Drugs, Immunosuppressant’s, Vaccines, Immunoglobulin’s, Corticosteroids, Targeted Therapy, and Chemotherapy), by Disease Type (Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liv

Chronic Liver Diseases Therapeutics Market, by Treatment Type (Antiviral Drugs, Immunosuppressant’s, Vaccines, Immunoglobulin’s, Corticosteroids, Targeted Therapy, and Chemotherapy), by Disease Type (Hepatitis, Autoimmune Diseases, Non-alcoholic Fatty Liver Disease (NAFLD), Cancer, Genetic Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

The liver is the largest solid internal organ of the body which performs various roles that include creation of bile for food digestion, converting food into energy, and maintaining an adequate level of the chemical in the body that stores nutrients for all cellular and biological activities. Therefore, improper functioning of the liver can cause many severe diseases which include hepatitis A, B, C, primary cirrhosis, and tumors. Some of the paramount reasons for improper functioning of the liver are obesity, excessive alcohol consumption, and genetic disorder. The treatment option available to treat liver diseases includes antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. Moreover, chronic liver diseases include hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and others.
Market Dynamics
The increasing population of chronic liver diseases, rising research and development activities for the development of novel technology for the treatment of liver diseases, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global chronic liver diseases therapeutics market over the forecast period.
For instance, Primary Sclerosing Cholangitis (PSC), is a chronic disease in which the bile duct inside and outside the liver become inflamed and scarred, eventually narrowed and blocked, subsequently, bile builds up in the liver and causes liver damage. According to National Institute of Health Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a worldwide prevalence of 25%. In the U.S, NAFLD and its subtype, nonalcoholic steatohepatitis, affect 30% and 5% of the population respectively.
Key features of the study:
This report provides an in-depth analysis of the global chronic liver diseases therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global chronic liver diseases therapeutics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global chronic liver diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic liver diseases therapeutics market

Detailed Segmentation:
Global Chronic Liver Diseases Therapeutics Market, By Treatment Type:
Antiviral Drugs
Immunosuppressants
Vaccines
Immunoglobulins
Corticosteroids
Targeted Therapy
Chemotherapy
Global Chronic Liver Diseases Therapeutics Market, By Disease Type:
Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorder
Others
Global Chronic Liver Diseases Therapeutics Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Chronic Liver Diseases Therapeutics Market, By Region:
North America
By Treatment Type
Antiviral Drugs
Immunosuppressant’s
Vaccines
Immunoglobulin’s
Corticosteroids
Targeted Therapy
Chemotherapy
By Disease Type
Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Treatment Type
Antiviral Drugs
Immunosuppressant’s
Vaccines
Immunoglobulin’s
Corticosteroids
Targeted Therapy
Chemotherapy
By Disease Type
Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Treatment Type
Antiviral Drugs
Immunosuppressant’s
Vaccines
Immunoglobulin’s
Corticosteroids
Targeted Therapy
Chemotherapy
By Disease Type
Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Treatment Type
Antiviral Drugs
Immunosuppressant’s
Vaccines
Immunoglobulin’s
Corticosteroids
Targeted Therapy
Chemotherapy
By Disease Type
Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Treatment Type
Antiviral Drugs
Immunosuppressant’s
Vaccines
Immunoglobulin’s
Corticosteroids
Targeted Therapy
Chemotherapy
By Disease Type
Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Treatment Type
Antiviral Drugs
Immunosuppressant’s
Vaccines
Immunoglobulin’s
Corticosteroids
Targeted Therapy
Chemotherapy
By Disease Type
Hepatitis
Autoimmune Diseases
Non-alcoholic Fatty Liver Disease (NAFLD)
Cancer
Genetic Disorders
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Astellas Pharma Inc.*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline Plc
Hoffmann-La Roche Ltd
Merck & Co. Inc
Novartis AG
Sanofi S.A
Pfizer Inc
Takeda Pharmaceutical
Valeant Pharmaceuticals
Watson Pharmaceuticals
Theratechnologies Inc
Alnylam Pharmaceuticals, Inc
Protagonist Therapeutics, Inc
Dicerna Pharmaceuticals, Inc
Endo International
Provectus Biopharmaceuticals Inc
MAX BioPharma, Inc.

“*” marked represents similar segmentation in other categories in the respective section.